49 results on '"Fung, Winston Wing-Shing"'
Search Results
2. Urinary podocyte stress marker as a prognostic indicator for diabetic kidney disease
- Author
-
Zeng, Lingfeng, Ng, Jack Kit-Chung, Fung, Winston Wing-Shing, Chan, Gordon Chun-Kau, Chow, Kai-Ming, and Szeto, Cheuk-Chun
- Published
- 2024
- Full Text
- View/download PDF
3. Plasma vaspin levels and clinical outcome in incident peritoneal dialysis patients
- Author
-
Than, Win Hlaing, Chan, Gordon Chun-Kau, Kwan, Bonnie Ching-Ha, Lai, Ka-Bik, Chan, Ronald Cheong-Kin, Teoh, Jeromy Yuen Chun, Ng, Jack Kit-Chung, Fung, Winston Wing-Shing, Chow, Kai-Ming, Cheng, Phyllis Mei-Shan, Li, Philip Kam-Tao, and Szeto, Cheuk-Chun
- Published
- 2023
- Full Text
- View/download PDF
4. Pharmacokinetics of Apixaban Among Peritoneal Dialysis Patients
- Author
-
Fung, Winston Wing-Shing, Cheng, Phyllis Mei-Shan, Ng, Jack Kit-Chung, Chan, Gordon Chun-Kau, Chow, Kai Ming, Li, Philip Kam-Tao, and Szeto, Cheuk Chun
- Published
- 2023
- Full Text
- View/download PDF
5. Omentin-1 Levels and Outcomes in Incident Peritoneal Dialysis Patients
- Author
-
Than, Win Hlaing, Chan, Gordon Chun-Kau, Kwan, Bonnie Ching-Ha, Lai, Ka-Bik, Chan, Ronald Cheong-Kin, Teoh, Jeromy Yuen Chun, Ng, Jack Kit-Chung, Fung, Winston Wing-Shing, Chow, Kai-Ming, Cheng, Phyllis Mei-Shan, Li, Philip Kam-Tao, and Szeto, Cheuk-Chun
- Published
- 2023
- Full Text
- View/download PDF
6. Circulating and Adipose Tissue Adiponectin Level and Outcomes in Incident Peritoneal Dialysis Patients
- Author
-
Than, Win Hlaing, Chan, Gordon Chun-Kau, Kwan, Bonnie Ching-Ha, Lai, Ka-Bik, Chan, Ronald Cheong-Kin, Teoh, Jeromy Yuen Chun, Ng, Jack Kit-Chung, Fung, Winston Wing-Shing, Chow, Kai-Ming, Cheng, Phyllis Mei-Shan, Law, Man-Ching, Li, Philip Kam-Tao, and Szeto, Cheuk-Chun
- Published
- 2023
- Full Text
- View/download PDF
7. Recombinant erythropoietin treatment improves serum podocyte marker levels in diabetic kidney disease
- Author
-
Zeng, Lingfeng, Ng, Jack Kit-Chung, Fung, Winston Wing-Shing, Chan, Gordon Chun-Kau, Chow, Kai-Ming, and Szeto, Cheuk-Chun
- Published
- 2023
- Full Text
- View/download PDF
8. Urinary and Kidney Podocalyxin and Podocin Levels in Diabetic Kidney Disease: A Kidney Biopsy Study
- Author
-
Zeng, Lingfeng, Fung, Winston Wing-Shing, Chan, Gordon Chun-Kau, Ng, Jack Kit-Chung, Chow, Kai-Ming, and Szeto, Cheuk-Chun
- Published
- 2023
- Full Text
- View/download PDF
9. Controversies in Living Kidney Donation
- Author
-
Fung, Winston Wing-Shing, Chapman, Jeremy, Nangaku, Masaomi, and Li, Philip Kam-Tao
- Published
- 2022
- Full Text
- View/download PDF
10. Urinary mi-106a for the diagnosis of IgA nephropathy: Liquid biopsy for kidney disease
- Author
-
Szeto, Cheuk-Chun, Ng, Jack Kit-Chung, Fung, Winston Wing-Shing, Chan, Gordon Chun-Kau, Luk, Cathy Choi-Wan, Lai, Ka-Bik, Wang, Gang, Chow, Kai-Ming, and Mac-Moune Lai, Fernand
- Published
- 2022
- Full Text
- View/download PDF
11. Adipose and serum zinc alpha-2-glycoprotein (ZAG) expressions predict longitudinal change of adiposity, wasting and predict survival in dialysis patients
- Author
-
Chan, Gordon Chun-Kau, Than, Win Hlaing, Kwan, Bonnie Ching-Ha, Lai, Ka-Bik, Chan, Ronald Cheong-Kin, Teoh, Jeremy Yuen-Chun, Ng, Jack Kit-Chung, Chow, Kai-Ming, Fung, Winston Wing-Shing, Cheng, Phyllis Mei-Shan, Law, Man-Ching, Leung, Chi-Bon, Li, Philip Kam-Tao, and Szeto, Cheuk-Chun
- Published
- 2022
- Full Text
- View/download PDF
12. Prognostic significance of peritoneal dialysis effluent mitochondrial DNA level
- Author
-
Than, Win Hlaing, Ng, Jack Kit-Chung, Fung, Winston Wing-Shing, Chan, Gordon Chun-Kau, Lai, Ka-Bik, Luk, Cathy Choi-Wan, Cheng, Phyllis Mei-Shan, Chow, Kai-Ming, and Szeto, Cheuk-Chun
- Published
- 2021
- Full Text
- View/download PDF
13. Kidney microRNA-21 Expression and Kidney Function in IgA Nephropathy
- Author
-
Szeto, Cheuk-Chun, Ng, Jack Kit-Chung, Fung, Winston Wing-Shing, Luk, Cathy Choi-Wan, Wang, Gang, Chow, Kai-Ming, Lai, Ka-Bik, Li, Philip Kam-Tao, and Lai, Fernand Mac-Moune
- Published
- 2021
- Full Text
- View/download PDF
14. Kidney Health for Everyone Everywhere – From prevention to detection and equitable access to care
- Author
-
Li, Philip Kam Tao, Garcia-Garcia, Guillermo, Andreoli, Sharon, Kalantar-Zadeh, Kamyar, Kumaraswami, Latha, Liakopoulos, Vassilios, Lui, Siu-Fai, Saadi, Gamal, Strani, Luisa, Ulasi, Ifeoma, Li, Philip Kam-Tao, Fung, Winston Wing-Shing, Hradsky, Anne, and Rakhimova, Ziyoda
- Published
- 2020
- Full Text
- View/download PDF
15. Kidney health for everyone everywhere-from prevention to detection and equitable access to care
- Author
-
Li, Philip Kam-Tao, Garcia-Garcia, Guillermo, Lui, Siu-Fai, Andreoli, Sharon, Fung, Winston Wing-Shing, Hradsky, Anne, and Kumaraswami, Latha
- Subjects
Chronic kidney failure -- Diagnosis -- Development and progression -- Prevention ,Health - Abstract
The global burden of chronic kidney disease (CKD) is rapidly increasing with a projection of becoming the 5th most common cause of years of life lost globally by 2040. Aggravatingly, CKD is a major cause of catastrophic health expenditure. The costs of dialysis and transplantation consume up to 3% of the annual healthcare budget in high-income countries. Crucially, however, the onset and progression of CKD are often preventable. In 2020, the World Kidney Day campaign highlights the importance of preventive interventions-be it primary, secondary, or tertiary. This complementing article focuses on outlining and analyzing measures that can be implemented in every country to promote and advance CKD prevention. Primary prevention of kidney disease should focus on the modification of risk factors and addressing structural abnormalities of the kidney and urinary tracts, as well as exposure to environmental risk factors and nephrotoxins. In persons with pre-existing kidney disease, secondary prevention, including blood pressure optimization and glycemic control, should be the main goal of education and clinical interventions. In patients with advanced CKD, the management of comorbidities such as uremia and cardiovascular disease is a highly recommended preventative intervention to avoid or delay dialysis or kidney transplantation. Political efforts are needed to proliferate the preventive approach. While national policies and strategies for non-communicable diseases might be present in a country, specific policies directed toward education and awareness about CKD screening, management, and treatment are often lacking. Hence, there is an urgent need to increase awareness of the importance of preventive measures throughout populations, professionals, and policy makers., Author(s): Philip Kam-Tao Li [sup.1] , Guillermo Garcia-Garcia [sup.2] , Siu-Fai Lui [sup.3] , Sharon Andreoli [sup.4] , Winston Wing-Shing Fung [sup.1] , Anne Hradsky [sup.5] , Latha Kumaraswami [sup.6] [...]
- Published
- 2020
- Full Text
- View/download PDF
16. Gut permeability, circulating bacterial fragments and measures of congestion in peritoneal dialysis.
- Author
-
Li, Chuanlei, Ng, Jack Kit-Chung, Chan, Gordon Chun-Kau, Fung, Winston Wing-Shing, Lai, Ka-Bik, Poon, Peter Yam-Kau, Luk, Cathy Choi-Wan, Chow, Kai-Ming, and Szeto, Cheuk-Chun
- Subjects
PERITONEAL dialysis ,PERMEABILITY ,BACTERIAL DNA ,INSULIN resistance ,OVERALL survival - Abstract
Background Limited data exist on the association between gut permeability, circulating bacterial fragment and volume overload in peritoneal dialysis (PD) patients. We measured circulating bacterial fragments, N-terminal pro B-type natriuretic peptide (NT-proBNP), calprotectin and zonulin levels, and evaluate their association with the clinical outcomes in PD patients. Methods This was a single-center prospective study on 108 consecutive incident PD patients. Plasma endotoxin and bacterial DNA, and serum NT-proBNP, calprotectin and zonulin levels were measured. Primary outcomes were technique and patient survival, secondary outcomes were hospitalization data. Results There was no significant correlation between plasma endotoxin and bacterial DNA, and serum NT-proBNP, calprotectin and zonulin levels. The Homeostatic Model Assessment for Insulin Resistance (HOMA)-2β index, which represents insulin resistance, positively correlated with plasma bacterial DNA (r = 0.421, P < .001) and calprotectin levels (r = 0.362, P = .003), while serum NT-proBNP level correlated with the severity of volume overload and residual renal function. Serum NT-proBNP level was associated with technique survival even after adjusting for confounding factors [adjusted hazard ratio (aHR) 1.030, 95% confidence interval 1.009–1.051]. NT-proBNP level was also associated with patient survival by univariate analysis, but the association became insignificant after adjusting for confounding factors (aHR 1.010, P = .073). Similarly, NT-proBNP correlated with the number of hospitalizations and duration of hospitalization by univariate analysis, but the association became insignificant after adjusting for confounding factors. Conclusion There was no correlation between markers of gut permeability, circulating bacterial fragments and measures of congestion in PD patients. Bacterial fragments levels and gut permeability are both associated with insulin resistance. Serum NT-proBNP level is associated with the severity of volume overload and technique survival. Further studies are required to delineate the mechanism of high circulating bacterial fragment levels in PD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Longitudinal Changes of NF-κB Downstream Mediators and Peritoneal Transport Characteristics in Incident Peritoneal Dialysis Patients
- Author
-
Fung, Winston Wing-Shing, Poon, Peter Yam-Kau, Ng, Jack Kit-Chung, Kwong, Vickie Wai-Ki, Pang, Wing-Fai, Kwan, Bonnie Ching-Ha, Cheng, Phyllis Mei-Shan, Li, Philip Kam-Tao, and Szeto, Cheuk-Chun
- Published
- 2020
- Full Text
- View/download PDF
18. Author Correction: Metabolomic Changes of Human Proximal Tubular Cell Line in High Glucose Environment
- Author
-
Wei, Pascal Zhongping, Fung, Winston Wing-Shing, Ng, Jack Kit-Chung, Lai, Ka-Bik, Luk, Cathy Choi-Wan, Chow, Kai Ming, Li, Philip Kam-Tao, and Szeto, Cheuk Chun
- Published
- 2020
- Full Text
- View/download PDF
19. Metabolomic Changes of Human Proximal Tubular Cell Line in High Glucose Environment
- Author
-
Wei, Pascal Zhongping, Fung, Winston Wing-Shing, Ng, Jack Kit-Chung, Lai, Ka-Bik, Luk, Cathy Choi-Wan, Chow, Kai Ming, Li, Philip Kam-Tao, and Szeto, Cheuk Chun
- Published
- 2019
- Full Text
- View/download PDF
20. Urinary Long Non-Coding RNA Levels as Biomarkers of Lupus Nephritis.
- Author
-
Szeto, Cheuk-Chun, So, Ho, Poon, Peter Yam-Kau, Luk, Cathy Choi-Wan, Ng, Jack Kit-Chung, Fung, Winston Wing-Shing, Chan, Gordon Chun-Kau, Chow, Kai-Ming, Lai, Fernand Mac-Moune, and Tam, Lai-Shan
- Subjects
LUPUS nephritis ,GENETIC regulation ,GENE expression ,LINCRNA ,BIOMARKERS ,URINALYSIS - Abstract
Background: Emerging evidence suggests that long non-coding RNA (lncRNA) plays important roles in the regulation of gene expression. We determine the role of using urinary lncRNA as a non-invasive biomarker for lupus nephritis. Method: We studied three cohorts of lupus nephritis patients (31, 78, and 12 patients, respectively) and controls (6, 7, and 24 subjects, respectively). The urinary sediment levels of specific lncRNA targets were studied using real-time quantitative polymerase chain reactions. Results: The severity of proteinuria inversely correlated with urinary maternally expressed gene 3 (MEG3) (r = −0.423, p = 0.018) and ANRIL levels (r = −0.483, p = 0.008). Urinary MEG3 level also inversely correlated with the SLEDAI score (r = −0.383, p = 0.034). Urinary cancer susceptibility candidate 2 (CASC2) levels were significantly different between histological classes of nephritis (p = 0.026) and patients with pure class V nephritis probably had the highest levels, while urinary metastasis-associated lung carcinoma transcript 1 (MALAT1) level significantly correlated with the histological activity index (r = −0.321, p = 0.004). Urinary taurine-upregulated gene 1 (TUG1) level was significantly lower in pure class V lupus nephritis than primary membranous nephropathy (p = 0.003) and minimal change nephropathy (p = 0.04), and urinary TUG1 level correlated with eGFR in class V lupus nephritis (r = 0.706, p = 0.01). Conclusions: We identified certain urinary lncRNA targets that may help the identification of lupus nephritis and predict the histological class of nephritis. Our findings indicate that urinary lncRNA levels may be developed as biomarkers for lupus nephritis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Impact of Weight Gain on the Subsequent Survival of New Peritoneal Dialysis Patients.
- Author
-
Than, Win Hlaing, Ng, Jack Kit-Chung, Chan, Gordon Chun-Kau, Fung, Winston Wing-Shing, Chow, Kai-Ming, and Szeto, Cheuk-Chun
- Published
- 2023
- Full Text
- View/download PDF
22. From MIA to FIFA: The vicious matrix of frailty, inflammation, fluid overload and atherosclerosis in peritoneal dialysis.
- Author
-
Chan, Gordon Chun‐Kau, Fung, Winston Wing‐Shing, Szeto, Cheuk‐Chun, and Ng, Jack Kit‐Chung
- Subjects
- *
HYPERVOLEMIA , *PERITONEAL dialysis , *FRAILTY , *CHRONIC kidney failure , *INFLAMMATION - Abstract
Cardiovascular disease (CVD) is a major cause of mortality and morbidity in peritoneal dialysis (PD) patients. Two decades ago, the common co‐existence of malnutrition and systemic inflammation PD patients with atherosclerosis and CVD led to the proposed terminology of 'malnutrition‐inflammation‐atherosclerosis (MIA) syndrome'. Although the importance of malnutrition is well accepted, frailty represents a more comprehensive assessment of the physical and functional capability of the patient and encompasses the contributions of sarcopenia (a key component of malnutrition), obesity, cardiopulmonary as well as neuropsychiatric impairment. In recent years, it is also increasingly recognized that fluid overload is not only the consequence but also play an important role in the pathogenesis of CVD. Moreover, fluid overload is closely linked with the systemic inflammatory status, presumably by gut oedema, gastrointestinal epithelial barrier dysfunction and leakage of bacterial fragments to the systemic circulation. There are now a wealth of published evidence to show intricate relations between frailty, inflammation, fluid overload and atherosclerotic disease in patients with chronic kidney disease (CKD) and those on PD, a phenomenon that we propose the term 'FIFA complex'. In this system, frailty and atherosclerotic disease may be regarded as two patient‐oriented outcomes, while inflammation and fluid overload are two inter‐connected pathogenic processes. However, there remain limited data on how the treatment of one component affect the others. It is also important to define how treatment of fluid overload affect the systemic inflammatory status and to develop effective anti‐inflammatory strategies that could alleviate atherosclerotic disease and frailty. Summary at a Glance: There are intricate relations between frailty, inflammation, fluid overload and atherosclerotic disease in patients with chronic kidney disease (CKD) and those on peritoneal dialysis (PD).We propose the term 'FIFA complex', with frailty and atherosclerotic disease as two patient‐oriented outcomes, while inflammation and fluid overload as two inter‐connected pathogenic processes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Intrarenal and Urinary Glycogen Synthase Kinase-3 Beta Levels in Diabetic and Nondiabetic Chronic Kidney Disease.
- Author
-
Zeng, Lingfeng, Ng, Jack Kit-Chung, Fung, Winston Wing-Shing, Chan, Gordon Chun-Kau, Chow, Kai-Ming, and Szeto, Cheuk-Chun
- Subjects
GLYCOGEN synthase kinase-3 ,CHRONIC kidney failure ,DIABETIC nephropathies ,KIDNEY diseases ,PROGNOSIS - Abstract
Background: Renal glycogen synthase kinase-3 beta (GSK3β) overactivity has been associated with a diverse range of kidney diseases. GSK3β activity in urinary exfoliated cells was reported to predict the progression of diabetic kidney disease (DKD). We compared the prognostic value of urinary and intrarenal GSK3β levels in DKD and nondiabetic chronic kidney disease (CKD). Methods: We recruited 118 consecutive biopsy-proved DKD patients and 115 nondiabetic CKD patients. Their urinary and intrarenal GSK3β levels were measured. They were then followed for dialysis-free survival and rate of renal function decline. Results: DKD group had higher intrarenal and urinary GSK3β levels than nondiabetic CKD (p < 0.0001 for both), but their urinary GSK3β mRNA levels were similar. Urinary p-GSK3β level is statistically significantly correlated with the baseline estimated glomerular filtration rate (eGFR), but urinary GSK3β level by ELISA, its mRNA level, the p-GSK3β level, or the p-GSK3β/GSK3β ratio had no association with dialysis-free survival or the slope of eGFR decline. In contrast, the intrarenal pY216-GSK3β/total GSK3β ratio significantly correlated with the slope of eGFR decline (r = −0.335, p = 0.006) and remained an independent predictor after adjusting for other clinical factors. Conclusion: Intrarenal and urinary GSK3β levels were increased in DKD. The intrarenal pY216-GSK3β/total GSK3β ratio was associated with the rate of progression of DKD. The pathophysiological roles of GSK3β in kidney diseases deserve further studies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Excessive risk and poor outcome of hospital-acquired peritoneal dialysis-related peritonitis.
- Author
-
Szeto, Cheuk-Chun, Ng, Jack Kit-Chung, Fung, Winston Wing-Shing, Chan, Gordon Chun-Kau, Cheng, Phyllis Mei-Shan, Law, Man-Ching, Pang, Wing-Fai, Li, Philip Kam-Tao, Leung, Chi-Bon, and Chow, Kai-Ming
- Subjects
PERITONITIS ,RENAL replacement therapy ,PERITONEAL dialysis ,HOSPITAL admission & discharge - Abstract
Background Peritoneal dialysis (PD) is a home-based renal replacement therapy. Since hospital staff are not often familiar with PD and its complications, PD patients may have an excess risk of developing PD-related peritonitis during hospital admission for unrelated reasons, and the outcome may be affected. Methods We reviewed 371 episodes of hospital-acquired PD peritonitis in our center from 2000 to 2019. Their clinical characteristics and outcomes were compared with 825 episodes that required hospital admission and 1964 episodes that were treated as outpatient. Results Hospitalized PD patients had a significantly higher risk of developing peritonitis than outpatients [incident rate ratio 4.41 (95% confidence interval 3.95–4.91]. Hospital-acquired peritonitis episodes were more commonly culture negative. Bacterial isolates from the hospital-acquired episodes were more likely resistant to ceftazidime (P < .0001) than the other groups. The primary response rate, complete cure rate and overall mortality of the hospital-acquired episodes were 66.6%, 62.0%, and 23.2%, respectively, all worse than episodes that developed outside the hospital (P < .0001 for all). Conclusion PD patients admitted to the hospital had a 4-fold increase in the risk of developing peritonitis. Hospital-acquired peritonitis episodes were more likely culture negative and resistant to antibiotics. They also had a lower primary response rate, a lower complete cure rate and higher mortality than episodes that developed outside the hospital. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. Green nephrology: a series of mini reviews on minimizing the environmental impact of kidney health care
- Author
-
Smyth, Brendan, Pippias, Maria, Sandal, Shaifali, Fung, Winston Wing-Shing, Ethier, Isabelle, Kelly, Dearbhla, Hafiz, Ehab, Bagasha, Peace, Onu, Ugochi Chika, Bilchut, Workagegnehu Hailu, Bajpai, Divya, Jha, Vivekanand, and De Chiara, Letizia
- Published
- 2023
- Full Text
- View/download PDF
26. Kidney Health for Everyone Everywhere - From Prevention to Detection and Equitable Access to Care.
- Author
-
Li, Philip Kam-Tao, Garcia-Garcia, Guillermo, Lui, Siu-Fai, Andreoli, Sharon, Fung, Winston Wing-Shing, Hradsky, Anne, Kumaraswami, Latha, Liakopoulos, Vassilios, Rakhimova, Ziyoda, Saadi, Gamal, Strani, Luisa, Ulasi, Ifeoma, Kalantar-Zadeh, Kamyar, Li, Philip Kam-Tao, Fung, Winston Wing-Shing, and for the World Kidney Day Steering Committee
- Abstract
The global burden of chronic kidney disease (CKD) is rapidly increasing with a projection of becoming the 5th most common cause of years of life lost globally by 2040. Aggravatingly, CKD is a major cause of catastrophic health expenditure. The costs of dialysis and transplantation consume up to 3% of the annual healthcare budget in high-income countries. Crucially, however, the onset and progression of CKD is often preventable. In 2020, the World Kidney Day campaign highlights the importance of preventive interventions - be it primary, secondary or tertiary. This complementing article focuses on outlining and analyzing measures that can be implemented in every country to promote and advance CKD prevention. Primary prevention of kidney disease should focus on the modification of risk factors and addressing structural abnormalities of the kidney and urinary tracts, as well as exposure to environmental risk factors and nephrotoxins. In persons with pre-existing kidney disease, secondary prevention, including blood pressure optimization and glycemic control, should be the main goal of education and clinical interventions. In patients with advanced CKD, management of co-morbidities such as uremia and cardiovascular disease is a highly recommended preventative intervention to avoid or delay dialysis or kidney transplantation. Political efforts are needed to proliferate the preventive approach. While national policies and strategies for non-communicable diseases might be present in a country, specific policies directed toward education and awareness about CKD screening, management and treatment are often lacking. Hence, there is an urgent need to increase the awareness of the importance of preventive measures throughout populations, professionals and policy makers. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
27. change in the prevalence of obesity and new-onset diabetes in Chinese peritoneal dialysis patients over 25 years.
- Author
-
Than, Win Hlaing, Ng, Jack Kit-Chung, Chan, Gordon Chun-Kau, Fung, Winston Wing-Shing, Chow, Kai-Ming, and Szeto, Cheuk-Chun
- Subjects
PERITONEAL dialysis ,HEMODIALYSIS patients ,CHRONIC kidney failure ,OBESITY ,PROGNOSIS ,TYPE 2 diabetes - Abstract
Background The global prevalence of both obesity and end-stage kidney diseases (ESKDs) has increased in recent decades. Given the complicated interaction between obesity and ESKD, we examined the change in the prevalence of obesity in incident Chinese peritoneal dialysis (PD) patients over the past 25 years. Methods We reviewed the anthropometric measures of incident PD patients in a single Hong Kong center from 1995 to 2019. The results are reported in five 5-year periods. Patients with and without diabetes were analyzed separately, and the incidence of new-onset diabetes after PD was explored. Results We reviewed 1681 patients. Their mean age was 58.4 ± 12.5 years; 931 patients (55.4%) had pre-existing diabetes. From 1995–99 to 2015–19, the prevalence of obesity or overweight at the initiation of PD increased progressively for every 5-year period (from 21.9% to 26.2, 37.9, 42.7 and 47.3%, P < 0.001 for linearity). The increase in the prevalence of obesity or overweight was more pronounced in diabetic patients (from 33.7% to 59.6%) than non-diabetic ones (from 13.2% to 32.3%). Among nondiabetics patients, the incidence of new-onset diabetes after started on PD showed an insignificant rising trend during that period (from 18.0, 19.7, 17.8 and 22.4% to 23.3%, P = 0.106). The incidence of new-onset impaired fasting glucose or diabetes was significantly higher in obese or overweight patients than the others (56.9% versus 51.4%, P < 0.001). Conclusions The prevalence of obesity has increased substantially in both diabetic and nondiabetic new PD patients in Hong Kong over the past 25 years. The incidence of new-onset diabetes was significantly higher in new PD patients with pre-existing obesity or overweight than those without obesity. The prognostic implication and impacts on the healthcare system deserve further studies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. Extended antibiotic therapy for the prevention of relapsing and recurrent peritonitis in peritoneal dialysis patients: a randomized controlled trial.
- Author
-
Szeto, Cheuk-Chun, Ng, Jack Kit-Chung, Fung, Winston Wing-Shing, Chan, Gordon Chun-Kau, Cheng, Phyllis Mei-Shan, Lai, Ka-Bik, Pang, Wing-Fai, Chow, Kai-Ming, Leung, Chi-Bon, and Li, Philip Kam-Tao
- Subjects
PERITONEAL dialysis ,RANDOMIZED controlled trials ,PERITONITIS ,HEMODIALYSIS patients ,ANTIBIOTICS - Abstract
Background Relapsing and recurrent peritonitis episodes are major causes of technique failure in peritoneal dialysis (PD). We examined the efficacy of extended antibiotic therapy for the prevention of relapsing and recurrent peritonitis. Methods From February 2016 to November 2018 we recruited 254 PD patients who fulfilled the diagnostic criteria for PD peritonitis. They were randomized to a standard group, with the duration of intraperitoneal (IP) antibiotic treatment following the International Society for Peritoneal Dialysis (ISPD) guideline according to the causative microorganisms, and an extended group, with 1 extra week of IP antibiotics. The primary endpoint was relapsing, recurrent or repeat peritonitis episodes within 6 months. Results The primary endpoint developed in 36 and 29 patients of the extended and standard groups, respectively (28.3% versus 22.8%; P = 0.34). The rate of complete cure, without relapsing, recurrent or repeat peritonitis within 6 months, was 63.8 and 69.3% for the extended and standard groups, respectively (P = 0.35). Repeat peritonitis episodes were more common in the extended than the standard group (15.0% versus 5.5%; P = 0.013). Conclusions In patients with PD-related peritonitis, extending the antibiotic therapy for 1 extra week beyond the ISPD protocol should not be recommended. Extending the treatment does not reduce the risk of relapsing or recurrent peritonitis episodes but rather is associated with a higher risk of repeat peritonitis episodes. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
29. Kidney Health for Everyone Everywhere – From Prevention to Detection and Equitable Access to Care.
- Author
-
Li, Philip Kam-Tao, Garcia-Garcia, Guillermo, Lui, Siu-Fai, Andreoli, Sharon, Fung, Winston Wing-Shing, Hradsky, Anne, Kumaraswami, Latha, Liakopoulos, Vassilios, Rakhimova, Ziyoda, Saadi, Gamal, Strani, Luisa, Ulasi, Ifeoma, and Kalantar-Zadeh, Kamyar
- Subjects
KIDNEY diseases ,NON-communicable diseases ,CHRONIC kidney failure ,KIDNEYS ,HIGH-income countries ,URINARY organs ,HEMODIALYSIS facilities ,ORGAN transplant waiting lists - Abstract
The global burden of chronic kidney disease (CKD) is rapidly increasing with a projection of becoming the 5th most common cause of years of life lost globally by 2040. Aggravatingly, CKD is a major cause of catastrophic health expenditure. The costs of dialysis and transplantation consume up to 3% of the annual healthcare budget in high-income countries. Crucially, however, the onset and progression of CKD is often preventable. In 2020, the World Kidney Day campaign highlights the importance of preventive interventions – be it primary, secondary or tertiary. This complementing article focuses on outlining and analyzing measures that can be implemented in every country to promote and advance CKD prevention. Primary prevention of kidney disease should focus on the modification of risk factors and addressing structural abnormalities of the kidney and urinary tracts, as well as exposure to environmental risk factors and nephrotoxins. In persons with pre-existing kidney disease, secondary prevention, including blood pressure optimization and glycemic control, should be the main goal of education and clinical interventions. In patients with advanced CKD, management of co-morbidities such as uremia and cardiovascular disease is a highly recommended preventative intervention to avoid or delay dialysis or kidney transplantation. Political efforts are needed to proliferate the preventive approach. While national policies and strategies for non-communicable diseases might be present in a country, specific policies directed toward education and awareness about CKD screening, management and treatment are often lacking. Hence, there is an urgent need to increase the awareness of the importance of preventive measures throughout populations, professionals and policy makers. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. Reprint of: Kidney health for everyone everywhere—from prevention to detection and equitable access to care.
- Author
-
Li, Philip Kam-Tao, Garcia-Garcia, Guillermo, Lui, Siu-Fai, Andreoli, Sharon, Fung, Winston Wing-Shing, Hradsky, Anne, Kumaraswami, Latha, Liakopoulos, Vassilios, Rakhimova, Ziyoda, Saadi, Gamal, Strani, Luisa, Ulasi, Ifeoma, and Kalantar-Zadeh, Kamyar
- Published
- 2020
- Full Text
- View/download PDF
31. Kidney Health for Everyone Everywhere - from Prevention to Detection and Equitable Access to Care.
- Author
-
Philip Kam-Tao Li, Garcia-Garcia, Guillermo, Siu-Fai Lui, Andreoli, Sharon, Fung, Winston Wing-Shing, Hradsky, Anne, Kumaraswami, Latha, Liakopoulos, Vassilios, Rakhimova, Ziyoda, Saadi, Gamal, Strani, Luisa, Ulasi, Ifeoma, and Kalantar-Zadeh, Kamyar
- Subjects
HEMODIALYSIS patients ,GLYCEMIC control ,KIDNEY diseases ,NON-communicable diseases ,CHRONIC kidney failure ,KIDNEYS - Abstract
The global burden of chronic kidney disease (CKD) is rapidly increasing with a projection of becoming the 5th most common cause of years of life lost globally by 2040. Aggravatingly, CKD is a major cause of catastrophic health expenditure. The costs of dialysis and transplantation consume up to 3% of the annual healthcare budget in high-income countries. Crucially, however, the onset and progression of CKD is often preventable. In 2020, the World Kidney Day campaign highlights the importance of preventive interventions - be it primary, secondary or tertiary. This complementing article focuses on outlining and analyzing measures that can be implemented in every country to promote and advance CKD prevention. Primary prevention of kidney disease should focus on the modification of risk factors and addressing structural abnormalities of the kidney and urinary tracts, as well as exposure to environmental risk factors and nephrotoxins. In persons with pre-existing kidney disease, secondary prevention, including blood pressure optimization and glycemic control, should be the main goal of education and clinical interventions. In patients with advanced CKD, management of co-morbidities such as uremia and cardiovascular disease is a highly recommended preventative intervention to avoid or delay dialysis or kidney transplantation. Political efforts are needed to proliferate the preventive approach. While national policies and strategies for non-communicable diseases might be present in a country, specific policies directed toward education and awareness about CKD screening, management and treatment are often lacking. Hence, there is an urgent need to increase the awareness of the importance of preventive measures throughout populations, professionals and policy makers. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
32. Kidney Health for Everyone Everywhere—From Prevention to Detection and Equitable Access to Care.
- Author
-
Li, Philip Kam‐Tao, Garcia‐Garcia, Guillermo, Lui, Siu‐Fai, Andreoli, Sharon, Fung, Winston Wing‐Shing, Hradsky, Anne, Kumaraswami, Latha, Liakopoulos, Vassilios, Rakhimova, Ziyoda, Saadi, Gamal, Strani, Luisa, Ulasi, Ifeoma, and Kalantar‐Zadeh, Kamyar
- Subjects
CHRONIC kidney failure ,COST effectiveness ,HEALTH education ,HEALTH services accessibility ,MEDICAL care costs ,MEDICAL screening ,RISK assessment ,COMORBIDITY ,HEALTH literacy ,EARLY diagnosis ,DISEASE risk factors - Abstract
SUMMARY: The global burden of chronic kidney disease (CKD) is increasing with a projection of becoming the fifth leading cause of years of life lost globally by 2040. CKD is a major cause of catastrophic health expenditure. The costs of dialysis and transplantation consume up to 3% of the entire annual healthcare budget in high‐income countries. Crucially, however, both the onset and progression of CKD is potentially preventable. In 2020, the World Kidney Day campaign highlights the importance of preventive interventions—be it primary, i.e. to prevent de novo CKD, or secondary or tertiary, i.e. prevention of worsening early CKD or progression of more advanced CKD to end‐stage kidney disease, respectively. Primary prevention should focus on the modification of CKD risk factors and address the structural abnormalities of the kidney and urinary tracts, and exposure to environmental risk factors and nephrotoxins. In persons with pre‐existing kidney disease, secondary prevention, including blood pressure optimization, glycemic control and avoiding high‐protein high‐sodium diet should be the main goal of education and clinical interventions. In patients with moderate to advanced CKD, the management of comorbidities such as uremia and cardiovascular disease along with low‐protein diet are among the recommended preventative interventions to avoid or delay dialysis or kidney transplantation. Whereas national policies and strategies for noncommunicable diseases may exist in a country, specific policies directed toward education and awareness about CKD screening, prevention and treatment are often lacking. There is an urgent need to increase awareness for preventive measures throughout populations, professionals and policy makers. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
33. Relationship between Plasma Endocan Level and Clinical Outcome of Chinese Peritoneal Dialysis Patients.
- Author
-
Poon, Peter Yam-Kau, Ng, Jack Kit-Chung, Fung, Winston Wing-Shing, Chow, Kai-Ming, Kwan, Bonnie Ching-Ha, Li, Philip Kam-Tao, and Szeto, Cheuk-Chun
- Subjects
HEMODIALYSIS patients ,PERITONEAL dialysis ,BLOOD proteins ,SERUM albumin - Abstract
Background: Endocan is associated with endothelial dysfunction. In peritoneal dialysis (PD) patients, cardiovascular disease is a common cause of mortality. We examined the relationship between serum endocan level and clinical outcome of PD patients. Methods: We recruited 193 new PD patients (118 males, mean age 58.8 ± 11.6 years). Serum endocan levels were determined and stratified into tertile 1 (lowest) to 3 (highest). Nutritional status, arterial pulse wave velocity (PWV) and serum C-reactive protein (CRP) levels were measured. The patients were followed for at least 4 years for clinical outcomes. Results: For the whole cohort, patients with higher serum endocan levels had lower serum albumin and subjective global assessment score, higher carotid-femoral PWV, and higher serum CRP. For patients with suboptimal blood pressure (BP) control, cardiovascular event-free survival was 95.0, 95.5, and 78.5% for tertiles 1, 2, and 3 at 60 months respectively (p = 0.019). Multivariate Cox regression analysis showed that serum endocan level was an independent predictor of cardiovascular event-free survival. No association with cardiovascular event-free survival was found for patients with adequate BP control (95.0, 92.3, and 100% for tertile 1, 2, and 3 at 60 months, respectively, p = 0.6). Conclusions: Higher serum endocan level is associated with unfavourable nutritional, arterial and inflammatory conditions in PD patients. In patients with suboptimal BP control, higher serum endocan is also associated with worse cardiovascular outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
34. Bilious peritoneal dialysate in a peritoneal dialysis patient
- Author
-
Fung, Winston Wing Shing, Chow, Kai Ming, and Szeto, Cheuk Chun
- Published
- 2021
- Full Text
- View/download PDF
35. Correction to: Kidney health for everyone everywhere: from prevention to detection and equitable access to care.
- Author
-
Li, Philip Kam-Tao, Garcia-Garcia, Guillermo, Lui, Siu-Fai, Andreoli, Sharon, Fung, Winston Wing-Shing, Hradsky, Anne, Kumaraswami, Latha, Liakopoulos, Vassilios, Rakhimova, Ziyoda, Saadi, Gamal, Strani, Luisa, Ulasi, Ifeoma, Kalantar-Zadeh, Kamyar, for the World Kidney Day Steering Committee, and Li, Philip Kam Tao
- Published
- 2020
- Full Text
- View/download PDF
36. Clinical Characteristics and Kidney Outcomes in Chinese Patients with Autosomal Dominant Polycystic Kidney Disease.
- Author
-
Fung WW, Szeto CC, Chow KM, Cheng PM, Kwong VW, Lau SL, Pang WF, Chu WC, Ong ACM, Devuyst O, and Li PK
- Subjects
- Humans, Female, Male, Adult, China epidemiology, Middle Aged, Asian People, Glomerular Filtration Rate, Kidney pathology, East Asian People, Polycystic Kidney, Autosomal Dominant genetics
- Published
- 2024
- Full Text
- View/download PDF
37. De novo positive hepatitis B surface antigen after hepatitis B vaccination in dialysis patients.
- Author
-
Chao AC, Fung WW, Szeto CC, and Chow KM
- Subjects
- Humans, Renal Dialysis adverse effects, Risk Factors, Vaccination adverse effects, Hepatitis B virus, Hepatitis B Surface Antigens, Hepatitis B prevention & control
- Published
- 2023
- Full Text
- View/download PDF
38. Circulating and Adipose Tissue Adiponectin Level and Outcomes in Incident Peritoneal Dialysis Patients.
- Author
-
Than WH, Chan GC, Kwan BC, Lai KB, Chan RC, Teoh JYC, Ng JK, Fung WW, Chow KM, Cheng PM, Law MC, Li PK, and Szeto CC
- Abstract
Rationale & Objective: Cardiovascular disease is the major cause of mortality and morbidity in peritoneal dialysis (PD) patients. Adiponectin, a key adipokine, is related to obesity and insulin resistance. We determined the clinical and prognostic value of plasma adiponectin level and its adipose tissue messenger RNA (mRNA) expression in new PD patients., Study Design: Retrospective analysis of a prospective observational study., Setting & Participants: 152 new PD patients from a single center; 6 adults undergoing abdominal surgeries without kidney disease served as controls., Predictors: Plasma adiponectin level and its adipose tissue mRNA expression., Outcomes: Body build and composition, patient and technique survival., Analytical Approach: Adiponectin level and mRNA expression were grouped in quartiles for correlation analysis for body build and Cox regression for survival analysis., Results: The median plasma adiponectin level was 31.98 μg/mL (IQR, 16.81-49.49 μg/mL), and adiponectin mRNA expression in adipose tissue was 1.65 times higher than in controls (IQR, 0.98-2.63). There was a modest but statistically significant correlation between plasma adiponectin and its adipose tissue mRNA expression ( r = 0.40, P < 0.001). Plasma adiponectin level inversely correlated with body mass index, waist-hip ratio, mid-arm circumference, adipose tissue mass, plasma triglyceride ( r = -0.39, -0.38, -0.41, -0.38, and -0.30, respectively; P < 0.001 for all), as well as serum insulin level ( r = -0.24, P = 0.005). Similar correlations were present but less marked with adipose tissue adiponectin mRNA level. Neither plasma adiponectin level nor adipose tissue adiponectin mRNA level predicted patient or technique survival., Limitations: Observational study, single center, single baseline measurement., Conclusions: Plasma adiponectin level correlated with the degree of adiposity in new PD patients. However, neither plasma adiponectin level nor its adipose tissue mRNA expression was an independent prognostic indicator in kidney failure patients newly started on PD., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
39. Urinary and Kidney Podocalyxin and Podocin Levels in Diabetic Kidney Disease: A Kidney Biopsy Study.
- Author
-
Zeng L, Fung WW, Chan GC, Ng JK, Chow KM, and Szeto CC
- Abstract
Rationale & Objective: Diabetic kidney diseases (DKDs) are the most common cause of dialysis-dependent kidney disease around the world. Previous studies have suggested that urinary level of podocyte-associated molecules may predict the prognosis of DKD., Study Design: Observational cohort., Setting & Participants: 118 consecutive patients with biopsy-proven DKD; 13 nondiabetic patients with hypertensive nephrosclerosis as controls., Predictors: Urinary podocalyxin and podocin levels were obtained by quantitative polymerase chain reaction and enzyme-linked immunosorbent assay (ELISA) and the corresponding intrarenal levels by western blotting., Outcomes: Dialysis-free survival; kidney event-free survival; rate of kidney function decline in 12 months., Analytical Approach: Correlation and time to event analysis., Results: Urinary podocalyxin level was closely correlated with its messenger RNA (mRNA) level ( r = 0.562, P < 0.001), but this did not predict the progression of DKD. Intrarenal podocalyxin level had only modest correlation with its urinary mRNA and ELISA levels, was an independent predictor of dialysis-free survival (adjusted HR, 1.85; 95% CI, 1.21-2.82; P = 0.005), and showed an insignificant trend of predicting kidney event-free survival (adjusted HR, 1.36; 95% CI, 0.94-1.95; P = 0.10). Urinary podocin level by ELISA had a modest correlation with the rate of kidney function decline ( r = 0.238, P = 0.01) but did not predict dialysis-free survival., Limitations: Small sample size; lack of serial measurement., Conclusions: Intrarenal podocalyxin level, but not its urinary level, was an independent predictor of dialysis-free survival, whereas urinary podocin level by ELISA correlated with the rate of kidney function decline. Although intrarenal podocalyxin level has prognostic value, it may not be suitable for routine clinical use., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
40. The Clinical Utility of the Neutrophil-to-Lymphocyte Ratio as a Discriminatory Test among Bacterial, Mycobacterium Tuberculosis , and Nontuberculous Mycobacterium Peritoneal Dialysis-Related Peritonitis.
- Author
-
Fung WW, Chow KM, Ng JK, Chan GC, Li PK, and Szeto CC
- Subjects
- Humans, Lymphocytes, Neutrophils, Nontuberculous Mycobacteria, Retrospective Studies, Mycobacterium tuberculosis, Peritoneal Dialysis adverse effects, Peritonitis diagnosis, Peritonitis, Tuberculous complications, Tuberculosis, Lymph Node complications
- Abstract
Background: Distinguishing Mycobacterium tuberculosis (TB) and nontuberculous Mycobacterium (NTM) from bacterial peritoneal dialysis (PD)-related peritonitis (peritonitis) is often very challenging and can lead to a significant delay in diagnosis and treatment. The neutrophil-to-lymphocyte ratio (NLR) is readily calculable and has been shown to be useful in differentiating pulmonary TB from bacterial pneumonia. We are the first group to demonstrate the predictive efficacy of peritoneal dialysate (PDE) NLR in distinguishing TB/NTM peritonitis from bacterial causes in the PD population., Methods: We retrospectively reviewed the clinical and laboratory characteristics of all patients with TB/NTM peritonitis, methicillin-sensitive Staphylococcus aureus (MSSA) peritonitis, and culture-negative peritonitis in our tertiary center between July 2000 and July 2020. The diagnostic ability of the blood and PDE NLR for differential diagnosis was evaluated., Results: In total, 258 episodes, 38 episodes, and 27 episodes were caused by MSSA, TB, and NTM species, respectively; 364 episodes were culture negative. The PDE NLR level taken at presentation were lowest in the TB peritonitis, followed by the NTM, culture-negative, and MSSA groups, (9.44±13.01, 16.99±23.96, 36.63±32.33, 48.51±36.01; P <0.001, respectively). The area under the receiver operating characteristic curve for the NLR taken at presentation was 0.83 (95% confidence interval, 0.77 to 0.89; P <0.001). A PDE NLR <15 was an optimal cut-off value with sensitivity, specificity, positive predictive value, and negative predictive values of 81%, 70%, 97%, and 22%, respectively., Conclusions: The PDE NLR obtained at presentation is a useful and easily accessible marker to discriminate TB/NTM peritonitis from bacterial peritonitis, especially in areas with intermediate TB/NTM burden. The NLR may enable early prompting of TB/NTM peritonitis, allowing specific investigation and treatment to be instigated earlier., Competing Interests: C. Szeto reports having consultancy agreements with Baxter Healthcare and Gilead Science; reports receiving research funding from Baxter Healthcare, Fibrogen Inc., Fresnius, and Gilead; reports receiving honoraria from Baxter Healthcare; reports having an advisory or leadership role with Baxter Healthcare and Gilead Science; and reports having other interests or relationships with AstraZeneca and Pfizer. P. Li reports having consultancy agreement with (2019) Fibrogen; reports being the Co-Chair of the advisory board for Treatment of Anemia in Peritoneal Dialysis Patients: What is the Asia Pacific Experience?; reports receiving honoraria from AstraZeneca for being a moderator for a symposium during the Asian Pacific Congress of Nephrology October 2020 and from Baxter on Modern PD Symposium May 2021; reports having an advisory or leadership role with Kidney International and Peritoneal Dialysis International; reports being Co-Chair for Fibrogen Advisory Board Meeting on Anemia in PD Patients (2019); and reports other interests or relationships as Immediate Past President, Asian Pacific Society of Nephrology, President, International Association of Chinese Nephrologists, and President, Hong Kong College of Physicians. The remaining authors have nothing to disclose., (Copyright © 2022 by the American Society of Nephrology.)
- Published
- 2022
- Full Text
- View/download PDF
41. Recent advances in novel diagnostic testing for peritoneal dialysis-related peritonitis.
- Author
-
Fung WW and Li PK
- Abstract
Peritoneal dialysis-related peritonitis remains a significant complication and an important cause of technique failure. Based on current International Society for Peritoneal Dialysis guidelines, diagnosis of peritonitis is made when two of the three following criteria are met: 1) clinical features consistent with peritonitis; 2) dialysis effluent white blood cell count of >100 cells/μL; 3) positive effluent culture. However, early and accurate diagnosis can still be faulty, and emphasis has been placed on improving the timeliness and accuracy of diagnosis to facilitate early effective treatment. There have been advances in the novel diagnostic tests such as point-of-care molecular tests, genetics sequencing, mass spectrometry, and machine learning algorithm with immune fingerprinting. This article will discuss the latest evidence and updates of these tests in the management of peritoneal dialysis-related peritonitis.
- Published
- 2022
- Full Text
- View/download PDF
42. Clinical course of peritoneal dialysis-related peritonitis due to non-tuberculosis mycobacterium - A single centre experience spanning 20 years.
- Author
-
Fung WW, Chow KM, Li PK, and Szeto CC
- Subjects
- Anti-Bacterial Agents therapeutic use, Ascitic Fluid, Humans, Nontuberculous Mycobacteria, Peritoneal Dialysis adverse effects, Peritonitis drug therapy, Peritonitis epidemiology, Peritonitis etiology
- Abstract
Background: Peritoneal dialysis (PD)-related peritonitis caused by non-tuberculous mycobacteria (NTM) are difficult to diagnose, is associated with significant morbidity and mortality, and clinical course remains unclear. We determined the prevalence and clinical course of peritonitis caused by these organisms through our kidney registry over 20-year period., Method: We reviewed all patients with NTM peritonitis identified in our tertiary centre between July 2000 and July 2020. The demographic characteristics, microbiological and clinical outcomes were examined., Result: Among 27 patients identified, 20 patients presented with abdominal pain and all had cloudy peritoneal fluid. Twenty-one cases had concomitant exit site infection and 14 cases had prior antibiotic use. The majority of the cases are caused by Mycobacterium chelonae (37%) and Mycobacterium fortuitum (29.7%), with most being resistant to fluoroquinolones (59.3%) and cefoxitin (73.1%). They are all sensitive to amikacin otherwise. None of the cases achieve primary response at day 10 and 20 cases resulted in Tenckhoff catheter removal. Only two of them were able to resume PD. Eight patients died in our cohort. The presence of exit site infection, the use of prior antibiotics and topical disinfectants did not associate with a poorer outcome., Conclusion: NTM peritonitis remains difficult to treat and often with a delay in diagnosis. Refractory peritonitis with negative culture and a poor response to standard antibiotics should raise a possibility of NTM infection and prompt catheter removal and an expert with experience treating NTM infections should be consulted.
- Published
- 2022
- Full Text
- View/download PDF
43. Nodular Lesions on the Hands of an ESKD Patient on Hemodialysis.
- Author
-
Fung WWS, Chow KM, and Szeto CC
- Subjects
- Humans, Hyperphosphatemia, Renal Dialysis adverse effects
- Abstract
Competing Interests: C. Szeto reports consultancy agreements with Baxter Healthcare and Gilead Science, has received research funding from Baxter Healthcare, Fresenius, Fibrogen, and Gilead, has received honoraria from Baxter Healthcare, serves as a scientific advisor or membership for Baxter Healthcare and Gilead Science, and has other interests or relationships with Pfizer and AstraZeneca. All remaining authors have nothing to disclose.
- Published
- 2021
- Full Text
- View/download PDF
44. The change in the prevalence of obesity and new-onset diabetes in Chinese peritoneal dialysis patients over 25 years.
- Author
-
Than WH, Ng JK, Chan GC, Fung WW, Chow KM, and Szeto CC
- Abstract
Background: The global prevalence of both obesity and end-stage kidney diseases (ESKDs) has increased in recent decades. Given the complicated interaction between obesity and ESKD, we examined the change in the prevalence of obesity in incident Chinese peritoneal dialysis (PD) patients over the past 25 years., Methods: We reviewed the anthropometric measures of incident PD patients in a single Hong Kong center from 1995 to 2019. The results are reported in five 5-year periods. Patients with and without diabetes were analyzed separately, and the incidence of new-onset diabetes after PD was explored., Results: We reviewed 1681 patients. Their mean age was 58.4 ± 12.5 years; 931 patients (55.4%) had pre-existing diabetes. From 1995-99 to 2015-19, the prevalence of obesity or overweight at the initiation of PD increased progressively for every 5-year period (from 21.9% to 26.2, 37.9, 42.7 and 47.3%, P < 0.001 for linearity). The increase in the prevalence of obesity or overweight was more pronounced in diabetic patients (from 33.7% to 59.6%) than non-diabetic ones (from 13.2% to 32.3%). Among nondiabetics patients, the incidence of new-onset diabetes after started on PD showed an insignificant rising trend during that period (from 18.0, 19.7, 17.8 and 22.4% to 23.3%, P = 0.106). The incidence of new-onset impaired fasting glucose or diabetes was significantly higher in obese or overweight patients than the others (56.9% versus 51.4%, P < 0.001)., Conclusions: The prevalence of obesity has increased substantially in both diabetic and nondiabetic new PD patients in Hong Kong over the past 25 years. The incidence of new-onset diabetes was significantly higher in new PD patients with pre-existing obesity or overweight than those without obesity. The prognostic implication and impacts on the healthcare system deserve further studies., (© The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA.)
- Published
- 2021
- Full Text
- View/download PDF
45. Clinical Spectrum and Renal Outcome of Cryoglobulinemia in Hong Kong.
- Author
-
Fung WW, Yip TC, Wong VW, Chow KM, Wong GL, and Szeto CC
- Subjects
- Cryoglobulins, Hong Kong epidemiology, Humans, Renal Dialysis adverse effects, Cryoglobulinemia epidemiology, Hepatitis C complications
- Abstract
Background: Cryoglobulinemia is a systemic disease and the clinical involvement is variable. The long-term renal outcome of cryoglobulinemia remains unclear, and most published series are from the Western world, with a high proportion of chronic hepatitis C. The objective is to determine the prevalence, causes, and renal outcome of cryoglobulinemia in Hong Kong., Methods: We reviewed 289 patients with cryoglobulinemia in the public hospital database of Hong Kong between 2000 and 2019. The renal event-free survival, dialysis-free survival, and overall survival were analyzed according to the underlying etiologies, and compared with 7483 patients who tested negative for cryoglobulinemia during the same period., Results: Among the patients with cryoglobulinemia, 68 (24%) had chronic hepatitis B, 69 (24%) had hepatitis C, and 14 (5%) paraproteinemia. They were followed for 62.7±58.0 months. The 5-year dialysis-free survival was 68%, 70%, 67%, and 83% for patients with cryoglobulinemia attributed to hepatitis B, hepatitis C, paraproteinemia, and unknown etiology, respectively ( P =0.05), and their 5-year overall survival was 61%, 58%, 22%, and 72%, respectively ( P =0.002). Among patients with hepatitis B, the group with cryoglobulin had a worse renal event-free survival than those without (36% versus 43%, P =0.005), although their dialysis-free survival and all-cause mortality were similar. For patients with hepatitis C or paraproteinemia, the presence of cryoglobulin did not affect the renal outcome., Conclusions: Hepatitis B is a common cause of cryoglobulinemia in southeast Asia, and the presence of cryoglobulinemia is associated with a worse renal event-free survival. The renal prognosis of cryoglobulinemia appears to be affected by the underlying cause, with hepatitis B having a worse renal outcome and patients with paraproteinemia having a worse overall survival than those with other causes of cryoglobulinemia., Competing Interests: C.-C. Szeto reports having consultancy agreements with Baxter Healthcare and Gilead Science; reports receiving research funding from Baxter Healthcare, Fibrogen Inc., Fresnius, and Gilead; reports receiving honoraria from Baxter Healthcare; reports being a scientific advisor or member of Baxter Healthcare and Gilead Science; and other interests/relationships with AstraZeneca and Pfizer. V.W.-S. Wong reports consultancy agreements with 3V-BIO, AbbVie, Allergan, Boehringer Ingelheim, Center for Outcomes Research in Liver Diseases, Echosens, Gilead Sciences, Hanmi Pharmaceutical, Intercept, Inventiva, Merck, Novartis, Novo Nordisk, Perspectum Diagnostics, Pfizer, ProSciento, Sagimet Biosciences, TARGET PharmaSolutions, and Terns; reports receiving research funding from Gilead Sciences; reports receiving honoraria from 3V-BIO, AbbVie, Allergan, Boehringer Ingelheim, Center for Outcomes Research in Liver Diseases, Echosens, Gilead Sciences, Hanmi Pharmaceutical, Intercept, Inventiva, Merck, Novartis, Novo Nordisk, Perspectum Diagnostics, Pfizer, ProSciento, Sagimet Biosciences, TARGET PharmaSolutions, and Terns; reports being a scientific advisor or member of the Clinical Gastroenterology and Hepatology and the editorial boards of the Journal of Hepatology, Hepatology, Alimentary Pharmacology and Therapeutics, Journal of Gastroenterology and Hepatology, JHEP Reports, and Hepatology Communications. All remaining authors have nothing to disclose., (Copyright © 2021 by the American Society of Nephrology.)
- Published
- 2021
- Full Text
- View/download PDF
46. Polymerase chain reaction/electrospray ionization-mass spectrometry (PCR/ESI-MS) is not suitable for rapid bacterial identification in peritoneal dialysis effluent.
- Author
-
Szeto CC, Ng JK, Fung WW, Lai KB, Chow KM, Li PK, Massiah A, Alcolea-Medina A, Wilks M, and Fan SL
- Subjects
- Bacteria genetics, Humans, Polymerase Chain Reaction, Spectrometry, Mass, Electrospray Ionization, Peritoneal Dialysis adverse effects, Peritonitis diagnosis, Peritonitis etiology
- Abstract
Background: Peritoneal dialysis (PD)-related peritonitis is a serious complication of PD, but routine microbiological culture is slow and could not identify the organism in 15% cases. We examine the accuracy of polymerase chain reaction/electrospray ionization-mass spectrometry (PCR/ESI-MS), a PCR-based method developed for the direct detection of bacteria in blood, for rapid identification of microorganisms from PD effluent., Methods: We recruited 73 consecutive patients with PD-related peritonitis. Dialysis effluent was collected for routine bacterial culture, PCR/ESI-MS, and bacterial DNA quantification before initiation of antibiotic therapy., Results: By digital PCR with universal bacterial primers, bacterial DNA was detectable in all PD effluent specimens. For the entire cohort, taking standard bacterial culture as the gold standard, the PCR/ESI-MS assay correctly identified 34.3% of the causative organisms, failed to identify any organism in 52.1% cases, and identified a different organism in 8.2% cases. For the 14 episodes of peritonitis that were culture negative by conventional bacterial culture, the PCR/ESI-MS assay identified an organism in only four cases. The detection rate of the IRIDICA BAC BSI assay was not affected by the use of biocompatible PD solution or concomitant exit-site infection., Conclusions: The PCR/ESI-MS assay could not identify the causative organism in over 50% of the PD effluent samples in patients with PD-related peritonitis and should be not used for such purpose. The reason for the poor performance needs further investigation.
- Published
- 2021
- Full Text
- View/download PDF
47. Kidney microRNA-21 Expression and Kidney Function in IgA Nephropathy.
- Author
-
Szeto CC, Ng JK, Fung WW, Luk CC, Wang G, Chow KM, Lai KB, Li PK, and Lai FM
- Abstract
Rationale & Objective: Previous studies have suggested that microRNA-21 (miR-21) plays an important role in kidney fibrosis. We examined the relationship between intrarenal miR-21 level and rate of kidney function loss in immunoglobulin A nephropathy (IgAN)., Study Design: Prospective cohort study., Setting & Participants: 40 patients with IgAN and 10 with hypertensive nephrosclerosis as controls., Predictors: miR-21 levels in kidney biopsy specimen and urinary sediment, quantified as ratio to the housekeeping gene., Outcomes: Kidney event-free survival and rate of kidney function decline., Analytic Approach: Time-to-event and correlation analysis., Results: The IgAN group had significantly higher intrarenal miR-21 expression compared with the hypertensive nephrosclerosis group (1.71 [IQR, 0.99-2.77] vs 0.31 [IQR, 0.25-1.32]; P < 0.0001), but urinary miR-21 levels were similar. Intrarenal miR-21 expression had significant but modest correlation with severity of glomerulosclerosis ( r = 0.293; P = 0.05) and tubulointerstitial fibrosis ( r = 0.341; P = 0.03). Patients with high intrarenal miR-21 expression had significantly higher risk for developing kidney end points compared with those with low expression (log-rank test, P = 0.017). Univariate Cox analysis showed that intrarenal miR-21 expression significantly predicted the development of kidney end points (unadjusted HR, 1.586; 95% CI, 1.179-2.134; P = 0.002). However, the result was just short of statistical significance after adjusting for the severity of histologic damage ( P = 0.06). There was also a significant correlation between intrarenal miR-21 expression and the slope of kidney function decline by univariate analysis ( r = -0.399; P = 0.02)., Limitations: Small sample size; uncertain cellular origin of miR-21., Conclusions: We found that intrarenal miR-21 expression is increased in patients with IgAN, modestly correlated with the severity of histologic damage, and predictive of subsequent kidney function loss., (© 2020 The Authors.)
- Published
- 2020
- Full Text
- View/download PDF
48. Kidney Health for Everyone Everywhere - From Prevention to Detection and Equitable Access to Care.
- Author
-
Li PK, Garcia-Garcia G, Lui SF, Andreoli S, Fung WW, Hradsky A, Kumaraswami L, Liakopoulos V, Rakhimova Z, Saadi G, Strani L, Ulasi I, and Kalantar-Zadeh K
- Abstract
The global burden of chronic kidney disease (CKD) is rapidly increasing with a projection of becoming the 5th most common cause of years of life lost globally by 2040. Aggravatingly, CKD is a major cause of catastrophic health expenditure. The costs of dialysis and transplantation consume up to 3% of the annual healthcare budget in high-income countries. Crucially, however, the onset and progression of CKD is often preventable. In 2020, the World Kidney Day campaign highlights the importance of preventive interventions - be it primary, secondary or tertiary. This complementing article focuses on outlining and analyzing measures that can be implemented in every country to promote and advance CKD prevention. Primary prevention of kidney disease should focus on the modification of risk factors and addressing structural abnormalities of the kidney and urinary tracts, as well as exposure to environmental risk factors and nephrotoxins. In persons with pre-existing kidney disease, secondary prevention, including blood pressure optimization and glycemic control, should be the main goal of education and clinical interventions. In patients with advanced CKD, management of co-morbidities such as uremia and cardiovascular disease is a highly recommended preventative intervention to avoid or delay dialysis or kidney transplantation. Political efforts are needed to proliferate the preventive approach. While national policies and strategies for non-communicable diseases might be present in a country, specific policies directed toward education and awareness about CKD screening, management and treatment are often lacking. Hence, there is an urgent need to increase the awareness of the importance of preventive measures throughout populations, professionals and policy makers., Competing Interests: All authors declare no competing interests., (Copyright © 2020 by S. Karger AG, Basel.)
- Published
- 2020
- Full Text
- View/download PDF
49. Straight Versus Coiled Peritoneal Dialysis Catheters: A Randomized Controlled Trial.
- Author
-
Chow KM, Wong SSM, Ng JKC, Cheng YL, Leung CB, Pang WF, Fung WWS, Szeto CC, and Li PKT
- Subjects
- Aged, Equipment Failure, Female, Humans, Male, Middle Aged, Peritonitis epidemiology, Catheters, Indwelling, Kidney Failure, Chronic therapy, Peritoneal Dialysis, Continuous Ambulatory instrumentation
- Abstract
Rationale & Objective: Despite a recent meta-analysis favoring straight catheters, the clinical benefits of straight versus coiled peritoneal dialysis catheters remain uncertain. We conducted a randomized controlled study to compare the complication rates associated with these 2 types of double-cuffed peritoneal dialysis catheters., Study Design: Multicenter, open-label, randomized, controlled trial., Setting & Participants: 308 adult continuous ambulatory peritoneal dialysis patients., Intervention: Participants were randomly assigned to receive either straight or coiled catheters., Outcomes: The primary outcome was the incidence of catheter dysfunction requiring surgical intervention. Secondary outcomes included time to catheter dysfunction requiring intervention, catheter migration with dysfunction, infusion pain measured using a visual analogue scale, peritonitis, technique failure, and peritoneal catheter survival., Results: 153 patients were randomly assigned to straight catheters; and 155, to coiled catheters. Among randomly assigned patients who underwent peritoneal dialysis, during a mean follow-up of 21 months, the primary outcome of catheter dysfunction or drainage failure occurred in 9 (5.8%) patients who received a coiled catheter and 1 (0.7%) patient who received a straight catheter. Straight catheters had 5.1% lower risk for catheter dysfunction (95% CI, 1.2%-9.1%; P=0.02). The HR of the primary outcome for coiled versus straight catheters was 8.69 (95% CI, 1.10-68.6; P=0.04). Patients who received a coiled catheter had similar risk for peritonitis but reported higher infusion pain scores than those who received straight catheters., Limitations: Generalizability to other peritoneal dialysis centers with lower volumes and other races and nationalities., Conclusions: Use of straight Tenckhoff catheters compared with coiled catheters reduced the rate of catheter dysfunction requiring surgical intervention., Funding: Funded by the Chinese University of Hong Kong., Trial Registration: Registered at ClinicalTrials.gov with study number NCT02479295., (Copyright © 2019 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.